argenx SE Investor Relations Material
Latest events
Q4 2023
argenx SE
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from argenx SE
Access all reports
argenx SE is a biotechnology firm based in Amsterdam, the Netherlands, specializing in the development of innovative therapies for autoimmune diseases. The company has developed a range of antibody-based medicines focusing on severe autoimmune conditions. Its flagship product, efgartigimod, targets various autoimmune disorders including myasthenia gravis and immune thrombocytopenia. argenx SE also collaborates with several partners to expand its research and development capabilities in immunology and oncology, highlighting its engagement in strategic alliances to advance its pipeline of therapeutic antibodies. The company is headquartered in Amsterdam, the Netherlands, and its shares are listed on the NASDAQ.
Key slides for argenx SE
Q4 2023
argenx SE
Status Update
argenx SE
Latest articles
Companies That Had Their IPO in 2019: Bull Market and Tech Dominance
Discussing the stock and IPO market in 2019, and the factors that led to the overall bullish performance of stocks during the year.
3 May 2024
Microsoft's Journey to Becoming the World's Most Valuable Company
Explore Microsoft's rise from a garage startup to the world's most valuable company, highlighting Bill Gates' role in shaping the digital revolution.
3 May 2024
Bill Gates: The Man Who Put a Computer in Every Home
Explore the life of Bill Gates, from co-founding Microsoft to global philanthropy, and his lasting impact on the world.
2 May 2024
Ticker symbol
Country
🇧🇪 Belgium